Detalhe da pesquisa
1.
MPL mutations in essential thrombocythemia uncover a common path of activation with eltrombopag dependent on W491.
Blood
; 135(12): 948-953, 2020 03 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-31978223
2.
Calreticulin mutants as oncogenic rogue chaperones for TpoR and traffic-defective pathogenic TpoR mutants.
Blood
; 133(25): 2669-2681, 2019 06 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-30902807
3.
JAK2 ex13InDel drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia vera.
Blood
; 134(26): 2388-2398, 2019 12 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-31697804
4.
Mutant JAK3 signaling is increased by loss of wild-type JAK3 or by acquisition of secondary JAK3 mutations in T-ALL.
Blood
; 131(4): 421-425, 2018 01 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-29187379
5.
Differential effect of inhibitory strategies of the V617 mutant of JAK2 on cytokine receptor signaling.
J Allergy Clin Immunol
; 144(1): 224-235, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30707971
6.
Cooperation of germ line JAK2 mutations E846D and R1063H in hereditary erythrocytosis with megakaryocytic atypia.
Blood
; 128(10): 1418-23, 2016 09 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-27389715
7.
Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms.
Blood
; 127(3): 325-32, 2016 Jan 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-26423830
8.
His499 Regulates Dimerization and Prevents Oncogenic Activation by Asparagine Mutations of the Human Thrombopoietin Receptor.
J Biol Chem
; 291(6): 2974-87, 2016 Feb 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-26627830
9.
Uncoupling JAK2 V617F activation from cytokine-induced signalling by modulation of JH2 αC helix.
Biochem J
; 473(11): 1579-91, 2016 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27029346
10.
Association Between Early Low-Dose Hydrocortisone Therapy in Extremely Preterm Neonates and Neurodevelopmental Outcomes at 2 Years of Age.
JAMA
; 317(13): 1329-1337, 2017 04 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28384828
11.
Cooperating JAK1 and JAK3 mutants increase resistance to JAK inhibitors.
Blood
; 124(26): 3924-31, 2014 Dec 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-25352124
12.
Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors.
Blood
; 123(9): 1372-83, 2014 Feb 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-24398328
13.
Orientation-specific signalling by thrombopoietin receptor dimers.
EMBO J
; 30(21): 4398-413, 2011 Sep 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-21892137
14.
Cooccurring JAK2 V617F and R1063H mutations increase JAK2 signaling and neutrophilia in myeloproliferative neoplasms.
Blood
; 132(25): 2695-2699, 2018 12 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-30377194
15.
Activating Janus kinase pseudokinase domain mutations in myeloproliferative and other blood cancers.
Biochem Soc Trans
; 41(4): 1048-54, 2013 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-23863177
16.
Constitutive activation and oncogenicity are mediated by loss of helical structure at the cytosolic boundary of thrombopoietin receptor mutant dimers.
Elife
; 122023 Jun 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-37338955
17.
Two-year neurodevelopmental outcomes of extremely preterm infants treated with early hydrocortisone: treatment effect according to gestational age at birth.
Arch Dis Child Fetal Neonatal Ed
; 104(1): F30-F35, 2019 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-29321180
18.
JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders.
F1000Res
; 7: 82, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29399328
19.
The S505A thrombopoietin receptor mutation in childhood hereditary thrombocytosis and essential thrombocythemia is S505N: single letter amino acid code matters.
Leukemia
; 33(2): 563-564, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30635630